Ischemix announced today the appointment of Patricia Baum as Clinical Trial Liaison. Ms. Baum was previously Cardiology Research Coordinator at the Lahey Clinic Medical Center in Burlington, MA.
"We are very pleased to welcome Ms. Baum to fill this newly created role within the Company. Her very strong background in clinical trial management, combined with her specific expertise in conducting clinical trials in the cardiac catheterization lab makes her an ideal addition to our team" said David DeWahl, President and CEO of the Company. He added "Patricia will work very closely with the clinical trial sites participating in our 240-subject CARIN trial, which is studying the ability of our lead compound, CMX-2043, to reduce the incidence of contrast-induced acute kidney injury ("CI-AKI") and peri-procedural MI in patients entering the cardiac catheterization lab."
Ms. Baum previously worked for Abiomed as Clinical Director, and at Biogen Idec, Brigham and Women's Hospital and the Cleveland Clinic. She received her BS in Nursing cum laude from Ursuline College. Ms. Baum was co-founder, first journal editor and president of the Society for Vascular Nursing. She is the author or co-author of numerous peer-reviewed journal articles.
Ischemix is a privately-held, clinical-stage pharmaceutical company developing a portfolio of novel cytoprotective compounds for the prevention and treatment of serious diseases and conditions. Cytoprotective compounds have broad potential therapeutic utility in multiple organ systems and disease states. The Company's lead product candidate, CMX-2043, is a patented, new chemical entity based on a naturally-occurring compound.
Ischemix has previously released positive data from SUPPORT-1, a 140-patient Phase 2a of CMX-2043, which demonstrated the ability of the compound to reduce the rise in biomarkers of cell death to a statistically significant degree in subjects undergoing PCI. Ischemix is currently enrolling subjects in a 240-patient CARIN trail to study the ability of CMX-2043 to reduce the incidence of contrast-induced acute kidney injury ("CI-AKI") and peri-procedural MI in patients entering the cardiac catheterization lab. The Company is also engaged in studying the use of CMX-2043 and other compounds for additional indications.
